| Effect | Decrease |
| Trial Design | Double blind |
| Trial Length | 1-2 Weeks |
| Number of Subjects | 2023 |
| Sex | Both Genders |
| Age Range | 0-1, 1-6, 7-12, 13-17, 18-29, 30-44, 45-64, 65+ |
Two weeks supplementation of EPs7630 to persons of all ages (30 drops thrice daily for adults, but 20 drops thrice daily for those between 6-12 and 10 drops thrice daily for those younger than 6) was able to significantly reduce overall symptoms as assessed by the BSS by around 86% with 68% of the sample reporting more than a 5 point reduction.
Most other comorbidities such as fever, fatigue, and headache were reduced in the range of 80-94.6%. Rhonchi (93.1% remission) chest pain during cough (94.1%), and shortness of breath (93.2%), but cough was only abolished in 56.2% of persons.
